AI Article Synopsis
Article Abstract
Background: Secondary hyperparathyroidism (SHPT) is a serious major complication in hemodialysis patients with chronic kidney disease. Long-term maintenance of serum phosphate, calcium, and parathyroid hormone (PTH) levels in appropriate ranges in these patients is a major challenge. We investigated the efficacy and safety of long-term treatment with etelcalcetide, a novel intravenous calcimimetic, in Japanese SHPT patients on long-term hemodialysis.
Methods: This study was a multicenter open-label study. A total of 191 hemodialysis patients with serum intact PTH (iPTH) > 240 pg/mL were enrolled. Etelcalcetide was administered thrice weekly for 52 weeks, with an initial dose of 5 mg and flexibility to adjust the dose between 2.5 and 15 mg and to adjust the dosing of concomitant medications for SHPT. The efficacy endpoint was the proportion of patients with serum iPTH decreased to the target range (60-240 pg/mL).
Results: Serum iPTH levels decreased immediately after etelcalcetide was started. At the end of the study, 87.5% (95% confidence interval 81.4-92.2; 140/160 patients) of patients achieved target serum iPTH levels, with control of serum calcium and phosphate levels. Adverse events, mostly mild to moderate, were reported by 96.8% of patients and led to study discontinuation in 7.4% of patients. Nausea, vomiting, and symptomatic hypocalcemia were found in 4.7, 9.5, and 1.1%, with 0.5, 1.1, and 1.1% considered treatment-related.
Conclusions: Etelcalcetide effectively maintained serum iPTH, calcium, and phosphate levels in appropriate ranges with concomitant medications for SHPT for 52 weeks in Japanese hemodialysis patients, and was safe and well tolerated.
Registration Number: JapicCTI-142665.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s10157-017-1442-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Endovascular Treatment of Malfunctioning Dialysis Fistulas: A Multicenter Retrospective Analysis Comparing Transradial and Conventional Transvenous Access.
Catheter Cardiovasc Interv
December 2024
Radiology Unit, University Hospital Dulbecco, Catanzaro, Italy.
Background: Venous outflow is the favored access for endovascular management of dialysis fistulas. However, transradial access (TRA) offers advantages in specific clinical scenarios. The study aims to compare the efficacy, feasibility, and safety of TRA and transvenous access (TVA) in the endovascular management of malfunctioning dialysis fistulas, addressing the existing gap in comprehensive literature.
View Article and Find Full Text PDFVitamin B12 deficiency in dialysis patients: risk factors, diagnosis, complications, and treatment: A comprehensive review.
World J Nephrol
December 2024
Department of Nephrology, Northwell Health-Staten Island University Hospital, Staten Island, NY 10305, United States.
Vitamin B12 deficiency is a significant concern among patients with end-stage renal disease undergoing dialysis. However, there hasn't been extensive research conducted on this particular patient group. The reported incidence rates vary widely, ranging from 20% to 90%, reflecting the complexity of its diagnosis.
View Article and Find Full Text PDFProbiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials.
World J Nephrol
December 2024
Department of Nephrology and Dialysis, State Institution "O.O. Shalimov National Scientific Center of Surgery and Transplantology of the National Academy of Medical Science of Ukraine", Kyiv 03680, Ukraine.
Peritoneal dialysis (PD) is a commonly used modality for kidney replacement therapy for patients with end-stage kidney disease (ESKD). PD offers many benefits, including home-based care, greater flexibility, and preservation of residual kidney function compared to in-center hemodialysis. Nonetheless, patients undergoing PD often face significant challenges, including systemic inflammation, PD-related peritonitis, metabolic disorders, and cardiovascular issues that can negatively affect their quality of life and treatment outcomes.
View Article and Find Full Text PDFFasting Glycemia, Glycosylated Hemoglobin and Malnutrition Inflammation Are Associated With Sarcopenia in Older People With Chronic Kidney Disease Undergoing Hemodialysis Treatment: A Cross-Sectional Study.
Cureus
November 2024
Department of Therapeutic Processes, Faculty of Health Sciences, Universidad Católica de Temuco, Temuco, CHL.
Background: Contradictory data are available on the possible association between sarcopenia and other clinical disorders in patients with chronic kidney disease (CKD) undergoing hemodialysis.
Objective: To determine the association between sarcopenia and markers associated with systemic inflammation, fasting glycemia, and quality of life in older people with CKD undergoing hemodialysis.
Methods: This was an analytical cross-sectional study.
Excessive water consumption from liquid or reconstituted oral nutrition supplements may increase risk of fluid overload in renal patients. Nutri-jelly, a ready-to-eat texture-modified diet with 52.8% water, some protein, low potassium, phosphorus, and sodium, could be an alternative.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!